Clinical potential of a new HIV protease inhibitor.

ABSTRACT

AIDS Based on favorable results from a phase I study of AG1343 using oral doses of 800 mg and 400 mg, a new study assessed a 300 mg dose regimen as the starting dose for a 1-month pilot phase II trial in HIV-positive patients with CD4 counts between 200 and 500. One patient was assessed who had been diagnosed in 1994 with HIV and had no prior HIV therapy or current medications. Results from HIV RNA titers, p24 antigen levels, and CD4 counts over a 9 to 14 day period showed increases in CD4 counts and decreases in viral load.^ieng